

Analyst

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: K. Takahashi, Y. Takeda, K. Nishiyama, M. Fukuyama, M. Maeki, A. Ishida, H. Tani, A. Imai, K. Shigemura, A. Hibara, H. Ogawa and M. Tokeshi, *Analyst*, 2026, DOI: 10.1039/D6AN00505E.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

Detection of H5 Subtype Avian Influenza Virus in Avian Oropharyngeal Swab Samples Using a Microfluidic Non-Competitive Fluorescence Polarization Immunoassay

Kazuki Takahashi¹, Yohei Takeda², Keine Nishiyama¹, Mao Fukuyama³, Masatoshi Maeki⁴, Akihiko Ishida⁴, Hirofumi Tani⁴, Ayuko Imai⁵, Koji Shigemura⁵, Akihide Hibara⁶, Haruko Ogawa⁷, Manabu Tokeshi^{4,8,9*}

¹*Graduate School of Chemical Sciences and Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo 060-8628, Japan*

²*Department of Veterinary Medicine, Obihiro University of Agriculture and Veterinary Medicine, 2-11 Inada, Obihiro, Hokkaido 080-8555, Japan*

³*Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1, Katahira, Aoba-ku, Sendai 980-8577, Japan*

⁴*Division of Applied Chemistry, Faculty of Engineering, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo 060-8628, Japan*

⁵*Tianma Japan, Ltd., Shinkawasaki Twin Tower West 28F, 1-1-2, Kashimada, Saiwai-ku, Kawasaki 212-0058, Japan*

⁶*Department of Chemistry, School of Science, Institute of Science Tokyo, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8551, Japan*

⁷*Research Center for Global Agromedicine, Obihiro University of Agriculture and Veterinary Medicine, 2-11 Inada, Obihiro, Hokkaido 080-8555, Japan*

⁸*Inovative Research Center for Preventive Medical Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan*

⁹*Institute of Nano-Life Systems, Institutes of Innovation for Future Society, Nagoya University, Furo-Cho, Chikusa-ku, Nagoya 464-8603, Japan*

*Corresponding author.

E-mail address: tokeshi@eng.hokudai.ac.jp (M.T).

Abstract

Rapid and simple methods for on-site detection of avian influenza virus (AIV) are essential for effective field surveillance. In this study, a microfluidic device-based non-competitive fluorescence polarization immunoassay (NC-FPIA) using an ATTO 647N-labeled hemagglutinin fragment of H5-AIV as a tracer was developed for the quantification of H5 subtype AIV (H5-AIV) in avian oropharyngeal swab samples. Autofluorescence from the swab matrix significantly interfered with fluorescence polarization measurements. However, quantitative detection of H5-AIV was achieved by suppressing the matrix effect through 80-fold dilution. The limit of detection was 186.4 $\mu\text{g/mL}$. The assay can be completed within 20 minutes without complex sample preparation, making it suitable for rapid on-site applications, including field surveillance of AIV in wild birds and poultry. Furthermore, by designing appropriate tracers, the method can be extended to other AIV subtypes.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Open Access Article. Published on 11 June 2016. Downloaded on 06/26/2016 3:26:18 AM.
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.



Introduction

In 2024, highly pathogenic avian influenza virus (HPAIV) was detected in dairy cattle in the United States for the first time^{1,2}, and human infections among dairy farm workers were also reported³. Such cross-species transmission has raised public health concerns, as it may indicate the potential for future adaptation of the virus to humans. In addition, HPAIV is transmitted from wild birds to poultry worldwide, leading to outbreaks that result in large-scale culling and supply disruptions. Consequently, significant economic impacts have been observed, including increases and volatility in the prices of poultry products such as chicken meat and eggs⁴. Thus, HPAIV poses a serious threat not only to public health but also to economic and social activities, highlighting the need to strengthen global surveillance systems from a One Health perspective^{5,6}. Among HPAIV subtypes, the H5N1 influenza virus is under intensive global surveillance as one of the most likely candidates for the next pandemic, owing to its documented human infections and high severity⁷. In addition, the H7N9 influenza virus⁸ and H5N6 influenza virus⁹, which have been reported to infect humans and are associated with severe disease, are also important targets of surveillance, along with subtypes such as the H5N8 influenza virus¹⁰, H9N2 influenza virus¹¹, and H5N3 influenza virus¹², which are considered to pose potential risks.

Current surveillance of avian influenza virus (AIV) relies on rapid antigen tests such as lateral flow assays (LFAs)^{13,14} for on-site screening, enzyme-linked immunosorbent assays (ELISAs)¹⁴ for laboratory-based antigen and antibody detection, and RT-PCR^{14,15} for confirmatory diagnosis. However, LFAs are generally limited to qualitative or semi-qualitative analysis and often suffer from insufficient sensitivity, particularly in complex biological specimens such as swab samples, serum, or tissue

sodium hydrosulfite (final concentration ~0.6%), followed by dialysis twice against 1000 volumes of PBS using regenerated cellulose membranes (MWCO 8,000; Repligen Corporation, MA, USA) to remove residual reagents. After dialysis, the concentration of inactivated H5N3 AIVs was measured again and adjusted to 0.5 mg/mL with PBS.

Preparation of tracers

Two types of tracers were synthesized by Hokudo Co., Ltd. (Sapporo, Japan) according to the following procedure. The anti-H5-HA rabbit IgG polyclonal antibodies were fragmented by papain digestion and purified using Protein A. The amino groups of the Fab fragments were labeled with HiLyte Fluor™ 647 and ATTO 647N according to the respective manufacturers' instructions. Unreacted fluorescent dyes were removed using a modified polyethersulfone membrane (Nanosep 3K Omega, Pall Corporation, NY, USA). The concentrations of the Fab fragments and fluorescent dyes were determined based on the absorbance at 280 nm and 500 nm measured using a fluorometer (NanoDrop One, Thermo Fisher Scientific, Inc.). The labeling efficiency (dye concentration/Fab fragment concentration) was 6.65 for HiLyte Fluor™ 647 and 5.22 for ATTO 647N.

Fluorescence and microfluidic-based fluorescence polarization measurement

To evaluate background fluorescence in fluorescence polarization measurements under conditions relevant to real-sample analysis, three-dimensional fluorescence spectra of oropharyngeal swab samples and VTM were measured. After tenfold dilution with ultrapure water, each sample was introduced into a quartz cuvette and analyzed by three-dimensional fluorescence (excitation-emission matrix, EEM) spectroscopy using a spectrofluorometer (F-7000, Hitachi High-Tech Corporation, Ibaraki, Japan) with



Quantification of H5N3 AIV using NC-FPIA

Purified H5N3 AIV was serially diluted twofold with PBS to prepare seven samples covering a concentration range of 6.6-850 $\mu\text{g/mL}$. Each diluted H5N3 AIV sample was mixed with ATTO-Fab at a fixed concentration of 120 ng/mL , 1% BSA solution, and PBS in a 0.5 mL microtube at a volume ratio of 7:1:1:1, resulting in a total sample volume of 50 μL . The mixture was incubated at 25 $^{\circ}\text{C}$ for 15 min. For blank measurements, PBS, ATTO-Fab, and 1% BSA solution were mixed at a ratio of 8:1:1 (50 μL). Fluorescence polarization measurements were performed in triplicate for each sample using the portable multichannel fluorescence polarization analyzer under the conditions described above.

Quantification of H5N3 AIV in avian oropharyngeal swab using NC-FPIA

Oropharyngeal swabs were collected from wild birds captured in Hokkaido and individual immersed in 1 mL of VTM. Swab samples obtained from approximately 20 individuals confirmed to be negative for influenza A virus were used as avian oropharyngeal swab samples in this study. To evaluate the autofluorescence of avian oropharyngeal swab samples, swab samples diluted 10- to 160-fold in PBS and ATTO-Fab (120 ng/mL) in PBS were each added (120 μL) to a 96-well black microplate (ProteoSaveTM 96F Plate (Black), Sumitomo Bakelite Co., Ltd., Tokyo, Japan), and the fluorescence intensity was measured using a plate reader (Infinite 200 PRO F Plex, Tecan, Männedorf, Switzerland) at an excitation wavelength of 620 nm and an emission wavelength of 670 nm. In the detection of H5N3 AIV in avian oropharyngeal swab samples, purified H5N3 AIV, diluted swab samples, 120 ng/mL ATTO-Fab, and 1% BSA solution were mixed in a 0.5 mL microtube at a volume ratio of 7:1:1:1 (50 μL) and



incubated at 25 °C for 15 min. Fluorescence polarization measurements were performed in triplicate for each sample using the portable multichannel fluorescence polarization analyzer under the conditions described above.

Results and discussion

Selection of a tracer

In general, when measuring real samples, signals originating from interfering substances other than the target analyte contribute to the background. Therefore, the EEM spectra of an avian oropharyngeal swab sample and VTM were measured (Fig. S1†). VTM was not only present in the swab samples used in this study, but it is also widely used as a medium for preserving and transporting samples collected from wild birds and poultry in the field, making it relevant to field surveillance. In previous studies, a fluorescein-labeled Fab that recognizes the HA of H5-AIV was used as a tracer²⁶. Accordingly, the portable fluorescence polarization analyzer was configured with an excitation wavelength of 470 nm and an emission detection range of 515- to 525 nm. Under these conditions, fluorescence was observed in both EEM spectra, indicating potential background interference. Notably, the swab sample exhibited stronger fluorescence than VTM. Based on these results, two fluorescent dyes, HiLyte Fluor™ 647 and ATTO 647N, were selected. These dyes have excitation wavelengths of approximately 644- to 649 nm and emission wavelengths of approximately 669- to 672 nm, where background interference is minimal.

Next, tracers labeled with these dyes were prepared, and their performance was evaluated. As in our previous work²⁶, these dyes were conjugated to Fab fragments that recognize the HA of H5-AIV, and HiLyte-Fab and ATTO-Fab were synthesized. Figure

lifetimes, since fluorescence polarization depends on the fluorescence lifetime of the dye. The larger ΔP observed for ATTO-Fab compared to HiLyte-Fab can be rationalized by the Perrin equation³¹:

$$P = P_0 / (1 + \tau/\theta)$$

where P is the fluorescence polarization, P_0 is the fundamental polarization, τ is the fluorescence lifetime, and θ is the rotational correlation time, which depends on the molecular size of the fluorophore-target complex. In the present study, the fluorescence lifetimes of ATTO 647N and HiLyte FluorTM 647 are 3.5 ns³² and 1.0 ns³³, respectively. The molecular weight of the Fab fragment is approximately 50 kDa, and the contribution of the fluorophore (843 Da³⁴ for ATTO 647N and 1303 Da³³ for HiLyte 647) is negligible. Therefore, the rotational correlation times of ATTO-Fab and HiLyte-Fab in the free (unbound) state can be considered nearly identical. Under these conditions, the longer fluorescence lifetime of ATTO-Fab results in a larger τ/θ value, leading to greater depolarization and thus a lower polarization compared to HiLyte-Fab. Consistent with this expectation, the polarization values of the free tracers were 180 mP for ATTO-Fab and 225 mP for HiLyte-Fab (data not shown). Upon binding to the avian influenza virus, which is a large particle with a diameter of approximately 80- to 120 nm³⁵ and an effective molecular weight on the order of 10⁸ Da, as estimated from its size and composition, the rotational correlation time becomes extremely large ($\theta \gg \tau$), and the polarization approaches the limiting value P_0 for both tracers. Consequently, the difference between the free and bound states ($\Delta P = P_{\text{bound}} - P_{\text{free}}$) is larger for ATTO-Fab than for HiLyte-Fab, primarily due to its lower initial polarization in the free state.

Quantification of H5N3 AIV using NC-FPIA

Figure 3 shows the calibration curve for purified H5N3 AIV in PBS. The ΔP increased with increasing H5N3 AIV concentration, demonstrating that purified H5N3 AIV can be quantified using the developed ATTO-Fab-based NC-FPIA. The limit of detection (LOD) for H5N3 AIV was determined to be 96 $\mu\text{g}/\text{mL}$, based on the average blank signal (control) plus three standard deviations. Although a strict direct comparison is not possible due to differences in dye and instrument optical properties as well as tracer concentration, comparison with the previous study²⁶ suggests that the present results may be more suitable for real sample analysis. In general, NC-FPIA exhibits a lower LOD when a lower tracer concentration is used²⁹. Therefore, in the previous study employing a lower tracer concentration of 80 ng/mL, the LOD was slightly better than that of the present work. However, in that study, ΔP appeared to be saturated in the high-concentration region of H5N3 AIV, with a maximum ΔP of only 13 mP, which may limit its applicability to real samples with high background signals. In contrast, in the present study, no saturation of ΔP was observed within the measured concentration range, and a larger signal change was obtained, with a maximum ΔP exceeding 30 mP.

Quantification of H5N3 AIV in avian oropharyngeal swab samples using NC-FPIA

Prior to quantifying H5N3 AIV in the avian oropharyngeal swab samples, the fluorescence intensity of the swab matrix itself was measured. Autofluorescence from the swab samples affects the measured P and should therefore be minimized as much as possible³⁶. Figure 4 compares the fluorescence intensity of swab samples diluted 10- to 160-fold in PBS and that of a 120 ng/mL ATTO-Fab solution. The dotted line indicates the fluorescence intensity of the ATTO-Fab solution. The autofluorescence of the swab samples became lower than that of the ATTO-Fab solution upon 80-fold dilution. Under

diseases such as classical swine fever, as well as other zoonotic viral infections, have become global concerns. The present method is therefore expected to be applicable to on-site surveillance of these infectious diseases.

Author contributions

K. T., Y. T., K. N., H. O., and M. T. conceived and designed the study. K. T., Y. T., K. N., and M. T. contributed to data collection and analysis. K. T., K. N., M. F., M. M., A. I., H. T., A. I., K. S., A. H., and M. T. joined discussions and provided constructive suggestions. K. T., Y. T., and M. T. wrote the initial draft of the manuscript. Y. T., M. F., M. M., A. I., H. T., A. I., K. S., A. H., H. O., and M. T. critically reviewed and made improvements in the manuscript. All authors approved the final version of the manuscript.

Conflict of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the JST-SENTAN program JPMJSN16A2. M.T. gratefully acknowledges Ryoto Watanabe, a student in his laboratory, for his assistance in preparing the figures.



References

1. A. J. Einfeld, A. Biswas, L. Guan, C. Gu, T. Maemura, S. Trifkovic, T. Wang, L. Babujee, R. Dahn, P. J. Halfmann, T. Barnhardt, G. Neumann, Y. Suzuki, A. Thompson, A. K. Swinford, K. M. Dimitrov, K. Poulsen, Y. Kawaoka, *Nature*, 2024, **633**, 426-432.
2. L. C. Caserta, E. A. Frye, S. L. Butt, M. Laverack, M. Nooruzzaman, L. M. Covaleda, A. C. Thompson, M. P. Koscielny, B. Cronk, A. Johnson, K. Kleinhenz, E. E. Edwards, G. Gomez, G. Hitchener, M. Martins, D. R. Kapczynski, D. L. Suarez, E. R. A. Morris, T. Hensley, J. S. Beeby, M. Lejeune, A. K. Swinford, F. Elvinger, K. M. Dimitrov, D. G. Diel, *Nature*, 2024, **634**, 669-676.
3. T. M. Uyeki, S. Milton, C. A. Hamid, C. R. Webb, S. M. Presley, V. Shetty, S. N. Rollo, D. L. Martinez, S. Rai, E. R. Gonzales, K. L. Kniss, Y. Jang, J. C. Frederick, J. A. De La Cruz, J. Liddell, H. Di, M. K. Kirby, J. R. Barnes, C. T. Davis, *N. Engl. J. Med.*, 2024, **390**, 2028-2029.
4. Z. Nisaa, B. Häsler, H. Bannani, R. Jorquera, F. Scolamacchia, P. Alarcon, *Prev. Vet. Med.*, 2026, **251**, 106827.
5. Food and Agriculture Organization of the United Nations. One Health approach to avian influenza: Protecting food security and human health. <https://www.fao.org/one-health/highlights/one-health-approach-to-avian-influenza/en> (accessed April 10, 2026).
6. European Commission. A One Health approach to zoonotic avian influenza. https://health.ec.europa.eu/one-health/zoonotic-threats/one-health-approach-zoonotic-avian-influenza_en (accessed April 10, 2026).
7. World Health Organization. Global Influenza Programme. <https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus> (accessed April 14, 2026).
8. R. Cao, B. Cao, Y. Hu, Z. Feng, D. Wang, W. Hu, J. Chen, Z. Jie, H. Qiu, K. Xu, X. Xu, H. Lu, W. Zhu, Z. Gao, N. Xiang, Y. Shen, Z. He, Y. Gu, Z. Zhang, Y. Yang, X. Zhao, L. Zhou, X. Li, S. Zou, Y. Zhang, X. Li, L. Yang, J. Guo, J. Dong, Q. Li, L. Dong, Y. Zhu, T. Bai, S. Wang, P. Hao, W. Yang, Y. Zhang, J. Han, H. Yu, D. Li, G. F. Gao, G. Wu, Y. Wang, Z. Yuan, Y. Shu, *N. Engl. J. Med.*, **368**, 1888-1897 (2013).
9. Z. Zhao, Z. Guo, C. Zhang, L. Liu, L. Chen, C. Zhang, Z. Wang, Y. Fu, J. Li, H. Shao, Q. Luo, J. Qian, L. Liu, *Sci. Rep.*, 2017, **7**, 16280.
10. S. Rafique, F. Rashid, S. Mushtaq, A. Ali, M. Li, S. Luo, L. Xie, Z. Xie, *Fornt. Microbiol.*, **2023**, 14, 1200681.
11. T. P. Peacock, J. James, J. E. Sealy, M. Iqbal, *Viruses*, 2019, **11**, 620.

12. R. M. Cha, Y. Jang, M.-J. Park, J. Kim, J.-M. Kim, E. H. Lim, G.-B. Heo, S.-H. An, K.-N. Lee, Y.-J. Lee, E.-K. Lee, *Transbound. Emerg. Dis.*, **2026**, 2026, 8053623.
13. M.-W. Lin, I. A. Quintela, S. S. Sablani, C.-S. Lin, V. C. H. Wu, *J. Virol.*, **2025**, **99**, e0148425.
14. S. Azeem, K.-J. Yoon, *Viruses*, **2025**, **17**, 228.
15. European Commission. Breaking the spread of avian flu: new tools for faster detection. https://health.ec.europa.eu/one-health/zoonotic-threats/one-health-approach-zoonotic-avian-influenza_en (accessed April 14, 2026).
16. Q. Niu, Z. Jiang, L. Wang, X. Ji, G. Baele, Y. Qin, L. Lin, A. Lai, Y. Chen, M. Veit, S. Su, *Nat. Commun.*, **2025**, **16**, 3558.
17. O. Wakao, K. Satou, A. Nakamura, K. Sumiyoshi, M. Shirokawa, C. Mizokuchi, K. Shiota, M. Maeki, A. Ishida, H. Tani, K. Shigemura, A. Hibara and M. Tokeshi, *Rev. Sci. Instrum.*, **2018**, **89**, 024103.
18. O. Wakao, K. Satou, A. Nakamura, P. A. Galkina, K. Nishiyama, K. Sumiyoshi, F. Kurosawa, M. Maeki, A. Ishida, H. Tani, M. A. Proskurnin, K. Shigemura, A. Hibara and M. Tokeshi, *Lab Chip*, **2019**, **19**, 2581-2588.
19. A. Nakamura, M. Aoyagi, M. Fukuyama, M. Maeki, A. Ishida, H. Tani, K. Shigemura, A. Hibara, M. Tokeshi, *ACS Food Sci. Technol.*, **2021**, **1**, 1623-1628.
20. Y. Ogura, M. Fukuyama, M. Kasuya, K. Shigemura, S. A. Eremin, M. Tokeshi, *Anal. Sci.*, **2023**, **39**, 2001-2006.
21. S. Chida, K. Takahashi, M. Fukuyama, M. Kasuya, A. Imai, A. V. Zherdev, S. A. Eremin, M. Maeki, A. Ishida, H. Tani, K. Shigemura, A. Hibara, M. Tokeshi, *Anal. Sci.*, in press.
22. M. Fukuyama, A. Nakamura, K. Nishiyama, A. Imai, M. Tokeshi, K. Shigemura, A. Hibara, *Anal. Chem.*, **2020**, **92**, 14393-14397.
23. K. Nishiyama, Y. Takeda, M. Maeki, A. Ishida, H. Tani, K. Shigemura, A. Hibara, Y. Yonezawa, K. Imai, H. Ogawa, M. Tokeshi, *Sens. Actuators B*, **2020**, **316**, 128160.
24. K. Nishiyama, K. Takahashi, M. Fukuyama, M. Kasuya, A. Imai, T. Usukura, N. Maishi, M. Maeki, A. Ishida, H. Tani, K. Hida, K. Shigemura, A. Hibara, M. Tokeshi, *Biosens. Bioelectron.*, **2021**, **190**, 113414.
25. K. Takahashi, S. Chida, T. Suwatthanarak, M. Iida, M. Zhang, M. Fukuyama, M. Maeki, A. Ishida, H. Tani, T. Yasui, Y. Baba, A. Hibara, M. Okochi, M. Tokeshi, *Lab Chip*, **2022**, **22**, 2971-2977.
26. K. Nishiyama, Y. Takeda, K. Takahashi, M. Fukuyama, M. Maeki, A. Ishida, H. Tani, K. Shigemura, A. Hibara, H. Ogawa, M. Tokeshi, *Anal. Bioanal. Chem.*, **2021**, **413**, 4619-4623.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
27. C. Yu-Ting, R. Suzuki, Y. Fujioka, A. Ishida, A. Imai, M. Fukuyama, M. Kasuya, Y. Ohba, T. Fukuhara, K. Shigemura, A. Hibara, M. Maeki, M. Tokeshi, *ACS Omega*, 2025, **10**, 51228-51235.
28. P. A. Routledge, A. D. Hutchings, in *The Immunoassay Handbook*, ed by D. Wild, 4th ed., Elsevier, Oxford, 2013, pp.945-962.
29. K. Nishiyama, M. Fukuyama, M. Maeki, A. Ishida, H. Tani, A. Hibara, M. Tokeshi, *Sens. Actuators B*, 2021, **326**, 128982.
30. W. B. Dandliker, V. A. de Saussure, *Immunochemistry*, 1970, **7**, 799–828.
31. F. Perrin, *J. Phys. Radium.*, 1926, **7**, 390-401.
32. ATTO 647N, Leica Microsystems, <https://www.leica-microsystems.com/products/consumables/p/atto-647n/> (accessed April 17, 2026).
33. HiLyte™ Fluor 647, AnaSpec, <https://www.anaspec.com/en/catalog/hilyte-fluor-647-succinimidyl-ester-se-1-mg~a3542919-7812-4c81-b170-2c86e5022084> (accessed April 17, 2026).
34. <https://lifesciences.danaher.com/us/en/products/sku/ad-647n-31-leica.html> (accessed April 17, 2026).
35. E. Spackman, *Methods Mol. Biol.*, 2008, **436**, 1-6.
36. O. D. Hendrickson, N. A. Taranova, A. V. Zherdev, B. B. Dzantiev, S. A. Eremin, *Sensors*, 2020, **20**, 7132.



Figure captions

Figure 1 Fluorescence polarization analyzer (a) and microfluidic device (b) for NC-FPIA.

The analyzer has dimensions of W 35 cm × D 15 cm × H 15 cm and weighs 5.5 kg. The disposable 9-microchannel microfluidic device, capable of simultaneously analyzing nine samples, was fabricated by bonding a black PDMS substrate fabricated using soft lithography to a glass plate. The microchannels had a width of 200 μm and a depth of 900 μm. Samples were introduced into each microchannel (12 μL per microchannel) using a pipette through a 3D-printed interface.

Figure 2 Schematic illustration of NC-FPIA for H5-AIV detection using fluorophore-labeled Fab. Free fluorophore-labeled Fab undergoes rapid rotational motion in solution, and even when excited with polarized light, the emitted fluorescence becomes depolarized, resulting in a low fluorescence polarization. In contrast, when the fluorophore-labeled Fab binds to the HA of H5-AIV, the rotational motion of the resulting complex becomes slower, and the emitted fluorescence remains polarized, resulting in a high fluorescence polarization.

Figure 3 Dependence of polarization change (ΔP) on tracer concentration. H5N3 AIV concentration was 850 μg/mL. Bars represent mean values, with error bars indicating standard deviation ($n = 3$). $\Delta mP = 10^3 \times \Delta P (= P_{\text{sample}} - P_{\text{control}})$.

Figure 4 Calibration curves for purified H5N3 AIV obtained at an ATTO-Fab concentration of 120 ng/mL. For the measurements, purified H5N3 AIV, PBS, 120 ng/mL ATTO-Fab solution, and 1% BSA solution were mixed in a volume ratio of 7:1:1:1. Data points represent mean values ($n = 3$), with error bars

1
2
3
4
5
6 indicating standard deviation. The solid line represents the fitted curve based on
7
8 the four-parameter logistic (4PL) model. $\Delta mP = 10^3 \times \Delta P (= P_{\text{sample}} - P_{\text{control}})$.

9
10 Figure 5 Fluorescence intensity as a function of the dilution factor of avian oropharyngeal
11
12 swab samples. Bars represent mean values (n = 3), with error bars indicating
13
14 standard deviation. The dashed line indicates the fluorescence intensity of
15
16 ATTO-Fab (120 ng/mL).

17
18 Figure 6 Calibration curve for H5N3 AIV in avian oropharyngeal swab samples at an
19
20 ATTO-Fab concentration of 120 ng/mL. For the measurements, purified H5N3
21
22 AIV, diluted swab samples, 120 ng/mL ATTO-Fab solution, and 1% BSA
23
24 solution were mixed in a volume ratio of 7:1:1:1. Data points represent mean
25
26 values (n = 3), with error bars indicating standard deviation. The solid line
27
28 represents the fitted curve based on the four-parameter logistic (4PL) model.
29
30 $\Delta mP = 10^3 \times \Delta P (= P_{\text{sample}} - P_{\text{control}})$.



Date availability

All the experimental data are presented in the main text and supplementary information (SI). Supplementary information is available. See DOI: <https://doi.org/10.1039/XXXX>. Other information is available upon reasonable request from the corresponding author.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Open Access Article. Published on 1 June 2026. Downloaded on 6/26/2026 6:26:18 AM.
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.




Analyst Accepted Manuscript

Figure 1

a




b



1
1
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Open Access Article. Published on 11 June 2016. Downloaded on 6/11/16. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.

Figure 2



41



Figure 3







Figure
4

Figure 5



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Figure
6

Date availability

All the experimental data are presented in the main text and supplementary information (SI). Supplementary information is available. See DOI: <https://doi.org/10.1039/XXXX>.

Other information is available upon reasonable request from the corresponding author.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Open Access Article. Published on 1 June 2026. Downloaded on 6/2/2026 6:26:18 AM.
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.



Analyst Accepted Manuscript